Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › complicated intra-abdominal infection

Complicated intra-abdominal infection

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for complicated intra-abdominal infection

12 trials tracked for complicated intra-abdominal infection: 8 in phase 3 or 4 and 5 with published results. The most-cited published study has 108 citations.

12Trials tracked
8Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 8 Phase 2 3 Other / NA 1
  1. Phase 3 A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. Completed · 108 cited
  2. Phase 3 Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections Completed · 100 cited
  3. Phase 3 Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) Completed · 25 cited
  4. Phase 3 Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013) Completed · 23 cited
  5. Phase 3 Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection Completed · 2 cited
  6. Phase 3 Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens Completed
Show 6 more trials
  1. Phase 3 Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections Completed
  2. Phase 3 Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections Completed
  3. Phase 2 MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) Completed
  4. Phase 2 Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections Completed
  5. Phase 2 Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections Completed
  6. N/A Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Complicated intra-abdominal infection: what the trials found

Clinical outcomes for complicated intra-abdominal infections (cIAI) vary across different antibiotic regimens. ATM-AVI demonstrated clinical cure rates of 68.4% to 77.0% depending on the analysis set 1. Ceftazidime-avibactam showed significant results in clinical cure proportions at the test of cure visit (p=<0.001) 2, while a study on CAZ-AVI reported low all-cause mortality rates at 28 days 7.

Other agents demonstrated high clinical response rates: Imipenem+Cilastarin/Relebactam showed a favorable clinical response in 85.7% of participants 3, and MK-7625A (ceftolozane/tazobactam) achieved a 92.0% clinical response rate at the test of cure visit 4. PF-06947386 showed high clinical response rates across multiple analysis sets, ranging from 90.0% to 94.6% 5.

The combination of CXA-201 and metronidazole demonstrated a clinical outcome of cure in 83.0% to 87.3% of the population at the test of cure visit, with microbiological success rates exceeding 94% 8.

Recent results — preliminary, needs further review

  • Ceftolozane/Tazobactam showed a clinical response of 'cure' in 80.0% to 100.0% of participants at the test of cure visit (not yet corroborated)
  • TP-434 was evaluated in a phase 2 study (not yet corroborated)

For the clinician treating this condition

  • Multiple antibiotic regimens, including ATM-AVI, Ceftazidime-avibactam, and combinations like CXA-201/metronidazole, have demonstrated clinical cure rates for cIAI.
  • High clinical response rates (90%+) were observed with treatments such as PF-06947386 and MK-7625A (ceftolozane/tazobactam).
  • Ceftazidime-avibactam showed statistically significant improvements in the proportion of patients with clinical cure at the test of cure visit 2.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review explores immunopathological framework for complicated intra-abdominal infection and intra-abdominal sepsis
Allergy & Immunology Sys. Review
Narrative review explores immunopathological framework for complicated intra-abdominal infection and intra-abdominal sepsis Abdominal Infections Turn Deadly in Hours — Here’s Why
This narrative review examines the compartment-oriented immunopathological framework as a conceptual alternative to traditionally source con…
A hidden immune switch in the belly can trap infection — or unleash life-threatening sepsis, depending on timing and health
Frontiers Apr 27, 2026